Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury

Blood

Volumn 96, Issue 8, 2000, Pages 2784-2792

  Lidington, Elaine A ^a   Haskard, Dorian O ^a   Mason, Justin C ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CD59 ANTIGEN; CYCLOHEXIMIDE; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE COFACTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME INHIBITOR; PROTEIN KINASE C; PROTEINASE ACTIVATED RECEPTOR 1; SYNAPTOPHYSIN; THROMBIN;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; ENZYME MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0034667689     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.8.2784.h8002784_2784_2792     Document Type: Article

References (74)

1. The complement system
2. Decay-accelerating factor: Biochemistry, molecular biology and function
3. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis
4. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of the complement activation gene cluster
5. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells
6. Production of platelet-activating factor by human vascular endothelial cells: Evidence for a requirement for specific agonists and modulation by prostacyclin
7. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro
8. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells
9. Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration
10. Thrombin-mediated increase in vascular endothelial permeability
11. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin
12. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression
13. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells
14. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway
15. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells
16. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils
17. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106)
18. Thrombin-induced p65 homodimer binding to down-stream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion
19. How the protease thrombin talks to cells
20. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1 - A mechanism for stabilizing neutrophil adhesion
21. Thrombin receptor 14-amino acid peptide binds to endothelial cells and stimulates calcium transients
22. Regulation of thrombin receptors on human umbilical vein endothelial cells
23. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets
24. Time course of recovery of endothelial cell surface thrombin receptor (PAR-1) expression
25. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
26. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis
27. Complement membrane attack on nucleated cells: Resistance, recovery and nonlethal effects
28. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition
29. Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells
30. Bradykinin- and thrombin-induced increases in endothelial permeability occur independently of phospholipase C but require, protein kinase C activation
31. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo
32. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-l, or lipopolysaccharide
33. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides
34. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
35. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
36. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B
37. Human Thy-1 is cytokine inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C
38. Single step method of RNA isolation by acid guanidium thiocyanatephenol-chloroform extraction
39. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement
40. Cellular consequences of thrombin-receptor activation
41. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of protein kinase C
42. Thrombin activates NF-kappa B through the thrombin receptor and results in proliferation of vascular smooth muscle cells: Role of thrombin in atherosclerosis and restenosis
43. Signaling pathways involved in thrombin-induced cell protection
44. 2 pathway: Evidence for cross-talk between ERK and p38 mitogen-activated protein kinase
45. Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in Interleukin-1beta- and tumor necrosis factor-alpha-induced low density lipoprotein receptor expression in HepG2 cells
46. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins
47. Endothelial cell decay-accelerating factor is Induced by vascular endothelial growth factor, is cytoprotective against activated complement and may be involved in regulating EC proliferation in chronic synovitis
48. Binding of workshop endothelial section mAb to resting activated human umbilical cord vein endothelial cells, platelets, and neutrophilic granulocytes
49. Thrombin-induced endothelial cell dysfunction
50. Endothelial cell responses to complement activation
51. Endothelial cells in physiology and in the pathophysiology of vascular disorders
52. Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation
53. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties
54. PAR3 is a cofactor for PAR4 activation by thrombin
55. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors
56. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors
57. One-way cross-talk between p38(MAPK) and p42/44(MAPK): Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade
58. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
59. p38 mitogen-activated protein kinase functionally contributes to chondregenesis induced by growth/differentiation factor-5 in ATDC5 cells
60. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
61. Complement activation occurs on subendothelial extracellular matrix
62. Relative inefficiency of terminal complement activation
63. IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis
64. Interferen gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture
65. Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma
66. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis
67. Membrane regulators of complement activation and their aberrant expression in disease
68. Immunohistochemical colocalizadon of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions
69. Thrombin receptor expression in normal and atherosclerotic human arteries
70. Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor
71. Complement-mediated regulation ot tissue factor activity in endothelium
72. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
73. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM- 1
74. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis